评估人体组织中的药物安全性——存在哪些障碍？ - Suppr

Suppr

超能文献

Assessing drug safety in human tissues - what are the barriers?

作者信息

Holmes Anthony, Bonner Frank, Jones David

机构信息

National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), London NW1 2BE, UK.

Stem Cells for Safer Medicines (SC4SM), London SW1E 6QT, UK.

出版信息

Nat Rev Drug Discov. 2015 Aug;14(8):585-7. doi: 10.1038/nrd4662. Epub 2015 Jul 24.

DOI:10.1038/nrd4662

PMID:26205467

Abstract

摘要

相似文献

Assessing drug safety in human tissues - what are the barriers?

Nat Rev Drug Discov. 2015 Aug;14(8):585-7. doi: 10.1038/nrd4662. Epub 2015 Jul 24.

New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.

Expert Opin Drug Metab Toxicol. 2016 May;12(5):475-7. doi: 10.1517/17425255.2016.1162292. Epub 2016 Mar 21.

Perspective of humanized mouse models for assessing PK/PD and toxic profile of drug candidates in preclinical study.

Drug Metab Pharmacokinet. 2014;29(1):1-2.

Navigating the risk landscape.

Nat Nanotechnol. 2016 Mar;11(3):211-2. doi: 10.1038/nnano.2016.28.

Consider drug efficacy before first-in-human trials.

Nature. 2017 Jan 30;542(7639):25-27. doi: 10.1038/542025a.

Introduction to nonclinical safety pharmacology and the safety pharmacology society.

J Pharmacol Toxicol Methods. 2004 May-Jun;49(3):141-4. doi: 10.1016/j.vascn.2004.02.004.

Drugs in control samples in nonclinical safety studies: a reconsideration.

Bioanalysis. 2016 May;8(10):1003-7. doi: 10.4155/bio-2016-0066. Epub 2016 Apr 15.

Zebrafish based assays for the assessment of cardiac, visual and gut function--potential safety screens for early drug discovery.

J Pharmacol Toxicol Methods. 2008 Jul-Aug;58(1):59-68. doi: 10.1016/j.vascn.2008.05.130. Epub 2008 Jun 8.

Safety immunopharmacology: evaluation of the adverse potential of pharmaceuticals on the immune system.

J Pharmacol Toxicol Methods. 2012 Sep;66(2):79-83. doi: 10.1016/j.vascn.2012.05.001. Epub 2012 May 14.

Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?

J Pharmacol Toxicol Methods. 2009 Jul-Aug;60(1):24-7. doi: 10.1016/j.vascn.2009.07.001. Epub 2009 Jul 15.

引用本文的文献

Induced Pluripotent Stem Cells, a Stepping Stone to In Vitro Human Models of Hearing Loss.

Cells. 2022 Oct 21;11(20):3331. doi: 10.3390/cells11203331.

Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.

Toxicol Sci. 2021 Apr 12;180(2):356-368. doi: 10.1093/toxsci/kfaa194.

Myocardial slices come to age: an intermediate complexity in vitro cardiac model for translational research.

Cardiovasc Res. 2020 Jun 1;116(7):1275-1287. doi: 10.1093/cvr/cvz341.

Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Nat Rev Drug Discov. 2020 Feb;19(2):131-148. doi: 10.1038/s41573-019-0048-x. Epub 2019 Nov 20.

Human-Derived Organ-on-a-Chip for Personalized Drug Development.

Curr Pharm Des. 2018;24(45):5471-5486. doi: 10.2174/1381612825666190308150055.

Adult Human Primary Cardiomyocyte-Based Model for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-arrhythmia Risk.

Front Physiol. 2017 Dec 19;8:1073. doi: 10.3389/fphys.2017.01073. eCollection 2017.

Cardiovascular Organ-on-a-Chip Platforms for Drug Discovery and Development.

Appl In Vitro Toxicol. 2016 Jun 1;2(2):82-96. doi: 10.1089/aivt.2016.0002.

Opportunities to Apply the 3Rs in Safety Assessment Programs.

ILAR J. 2016 Dec;57(2):234-245. doi: 10.1093/ilar/ilw024.

Human ex-vivo action potential model for pro-arrhythmia risk assessment.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:183-95. doi: 10.1016/j.vascn.2016.05.016. Epub 2016 May 25.

本文引用的文献

Organs-on-chips at the frontiers of drug discovery.

Nat Rev Drug Discov. 2015 Apr;14(4):248-60. doi: 10.1038/nrd4539. Epub 2015 Mar 20.

Accelerating drug discovery via organs-on-chips.

Lab Chip. 2013 Dec 21;13(24):4697-710. doi: 10.1039/c3lc90115g.

The future of the patient-specific Body-on-a-chip.

Lab Chip. 2013 Sep 21;13(18):3471-80. doi: 10.1039/c3lc50237f.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Assessing drug safety in human tissues - what are the barriers?

Nat Rev Drug Discov. 2015 Aug;14(8):585-7. doi: 10.1038/nrd4662. Epub 2015 Jul 24.

New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.

Expert Opin Drug Metab Toxicol. 2016 May;12(5):475-7. doi: 10.1517/17425255.2016.1162292. Epub 2016 Mar 21.

Perspective of humanized mouse models for assessing PK/PD and toxic profile of drug candidates in preclinical study.

Drug Metab Pharmacokinet. 2014;29(1):1-2.

Navigating the risk landscape.

Nat Nanotechnol. 2016 Mar;11(3):211-2. doi: 10.1038/nnano.2016.28.

Consider drug efficacy before first-in-human trials.

Nature. 2017 Jan 30;542(7639):25-27. doi: 10.1038/542025a.

Introduction to nonclinical safety pharmacology and the safety pharmacology society.

J Pharmacol Toxicol Methods. 2004 May-Jun;49(3):141-4. doi: 10.1016/j.vascn.2004.02.004.

Drugs in control samples in nonclinical safety studies: a reconsideration.

Bioanalysis. 2016 May;8(10):1003-7. doi: 10.4155/bio-2016-0066. Epub 2016 Apr 15.

Zebrafish based assays for the assessment of cardiac, visual and gut function--potential safety screens for early drug discovery.

J Pharmacol Toxicol Methods. 2008 Jul-Aug;58(1):59-68. doi: 10.1016/j.vascn.2008.05.130. Epub 2008 Jun 8.

Safety immunopharmacology: evaluation of the adverse potential of pharmaceuticals on the immune system.

J Pharmacol Toxicol Methods. 2012 Sep;66(2):79-83. doi: 10.1016/j.vascn.2012.05.001. Epub 2012 May 14.

Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?

J Pharmacol Toxicol Methods. 2009 Jul-Aug;60(1):24-7. doi: 10.1016/j.vascn.2009.07.001. Epub 2009 Jul 15.

引用本文的文献

Induced Pluripotent Stem Cells, a Stepping Stone to In Vitro Human Models of Hearing Loss.

Cells. 2022 Oct 21;11(20):3331. doi: 10.3390/cells11203331.

Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.

Toxicol Sci. 2021 Apr 12;180(2):356-368. doi: 10.1093/toxsci/kfaa194.

Myocardial slices come to age: an intermediate complexity in vitro cardiac model for translational research.

Cardiovasc Res. 2020 Jun 1;116(7):1275-1287. doi: 10.1093/cvr/cvz341.

Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Nat Rev Drug Discov. 2020 Feb;19(2):131-148. doi: 10.1038/s41573-019-0048-x. Epub 2019 Nov 20.

Human-Derived Organ-on-a-Chip for Personalized Drug Development.

Curr Pharm Des. 2018;24(45):5471-5486. doi: 10.2174/1381612825666190308150055.

Adult Human Primary Cardiomyocyte-Based Model for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-arrhythmia Risk.

Front Physiol. 2017 Dec 19;8:1073. doi: 10.3389/fphys.2017.01073. eCollection 2017.

Cardiovascular Organ-on-a-Chip Platforms for Drug Discovery and Development.

Appl In Vitro Toxicol. 2016 Jun 1;2(2):82-96. doi: 10.1089/aivt.2016.0002.

Opportunities to Apply the 3Rs in Safety Assessment Programs.

ILAR J. 2016 Dec;57(2):234-245. doi: 10.1093/ilar/ilw024.

Human ex-vivo action potential model for pro-arrhythmia risk assessment.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:183-95. doi: 10.1016/j.vascn.2016.05.016. Epub 2016 May 25.

本文引用的文献

Organs-on-chips at the frontiers of drug discovery.

Nat Rev Drug Discov. 2015 Apr;14(4):248-60. doi: 10.1038/nrd4539. Epub 2015 Mar 20.

Accelerating drug discovery via organs-on-chips.

Lab Chip. 2013 Dec 21;13(24):4697-710. doi: 10.1039/c3lc90115g.

The future of the patient-specific Body-on-a-chip.

Lab Chip. 2013 Sep 21;13(18):3471-80. doi: 10.1039/c3lc50237f.